Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

BPC-157 Fusion Proteins: Rat Readout

A 2026 BPC-157 study tested two bacteria-made fusion proteins in a rat stomach-ulcer model, not ordinary BPC-157 in people.

Why we wrote this. The headline sounds like a human BPC-157 advance. The actual work joins the peptide to larger proteins and tests them in an acute rat model.

In this article (5 sections)
  1. What the researchers made
  2. What happened in the rat ulcer model
  3. Why the fusion-protein detail matters
  4. The human evidence and safety gap
  5. What we do not know yet

A 2026 study did not test ordinary BPC-157 in people. It engineered Bacillus licheniformis bacteria to produce two larger fusion proteins containing the BPC-157 sequence, then tested those proteins in rats with chemically induced stomach ulcers. The abstract reports less visible ulceration and lower inflammatory markers after treatment[1]. That is an interesting manufacturing and animal result, but it does not establish that a commercial BPC-157 vial contains the same material, works in humans, or is safe to use.

What the researchers made

The production problem comes first. Small peptides can be difficult to express intact in bacteria because enzymes may degrade them and purification can be awkward. The researchers inserted genetic constructs into the chromosome of B. licheniformis strain 2709. One construct joined the BPC-157 sequence to gamma-glutamyltranspeptidase, shortened to GGT. The other joined it to mScarlet, a red fluorescent reporter protein. These are fusion proteins: BPC-157 is attached to a much larger protein rather than isolated as the familiar 15-amino-acid peptide[1].

The team adjusted the fermentation medium and inoculum, then used reporter signals as its expression readout. The abstract identifies 2% inoculum, 40 grams per litre of soybean peptone, and 80 grams per litre of glucose as the selected conditions. Under those conditions, reporter-based expression signals were about three times those in the basal medium. Fractional ammonium sulfate precipitation was then used to purify the fusion proteins, with different reported saturation points for the two constructs[1]. These details describe a bench production method. They are not a dosing recipe and say nothing about the identity or purity of products sold online.

What happened in the rat ulcer model

The biological test used rats with acute gastric injury caused by ethanol. In a protective regime, treatment preceded or accompanied the injury model; in a therapeutic regime, treatment addressed injury after induction. The abstract reports ulcer-inhibition rates from 75.3% to 82.9% in the protective experiments and from 80.4% to 84.6% in the therapeutic experiments. It also reports reduced mucosal inflammation, signs of glandular repair, and lower gastric-tissue concentrations of TNF-alpha, IL-1 beta, and IL-6[1]. Those cytokines are signalling proteins involved in inflammation.

The abstract does not provide the group sizes, randomisation method, blinding procedure, complete statistical results, adverse-event accounting, or a comparison against isolated BPC-157. The article is not available as open full text through PubMed or Europe PMC, so those details could not be independently checked from the accessible record. The reported percentages should therefore stay attached to this rat model and these two fusion proteins. They should not be converted into a human healing rate.

Why the fusion-protein detail matters

A fusion can alter stability, distribution, immune recognition, and the way a molecule interacts with tissue. The study may show that the engineered proteins retained biological activity in this model, but it does not prove that the attached BPC-157 sequence behaved like free BPC-157. The abstract also does not say that either fusion was cleaved to release the short peptide before treatment. Readers should not treat results for GGT-BPC157 or mScarlet-BPC157 as interchangeable with findings about an unmodified BPC-157 product.

This distinction also blocks a common leap from production research to product quality. Chromosomal integration in a named bacterial strain and precipitation in a laboratory do not validate a grey-market vial. They do not establish sequence identity, sterility, endotoxin control, peptide-related impurities, storage stability, or batch consistency. Those are separate analytical and manufacturing questions.

The human evidence and safety gap

The paper's final sentence suggests possible applications in gastric-ulcer treatment, but the experiment remains preclinical. No patient outcomes were reported. The accessible record contains no human pharmacokinetic data, dose-ranging work, repeated-exposure study, or clinical safety analysis. It also does not compare the fusion proteins with an approved ulcer treatment.

The US Food and Drug Administration separately lists BPC-157 among bulk substances that may present significant safety risks in compounding. The agency points to possible immunogenicity, which means an unwanted immune response, as well as peptide-impurity and active-ingredient-characterisation problems. FDA says it has no or only limited safety information for proposed administration routes and lacks enough information to know whether BPC-157 would harm humans[2]. A rat stomach-ulcer result does not resolve any of those concerns.

What we do not know yet

We do not know whether another laboratory can reproduce the reported expression gain or ulcer findings. We do not know how much intact fusion protein reached rat tissue, whether the BPC-157 segment separated from its carrier, or which part of either fusion drove the observed effect. We also do not know whether the apparent tissue response would persist, weaken, or create new risks with repeated exposure.

The experiment also cannot settle claims about BPC-157 safety or effects outside the stomach. An ethanol injury model is not a tendon tear, surgical wound, chronic ulcer, or inflammatory bowel condition. Different tissues expose a molecule to different enzymes and immune cells. A result in one short animal experiment needs replication before it can support a clinical hypothesis, much less a treatment claim. Our BPC-157 research summary keeps those evidence levels separate.

Most importantly, this study does not answer whether BPC-157 helps a person with an ulcer, tendon injury, or postoperative recovery. It supplies a possible bacterial production route and one acute animal-model readout. Anyone considering an unapproved peptide should discuss the evidence and product-quality uncertainty with a qualified clinician. For the broader evidence record and current status, see the BPC-157 overview and its regulatory summary.

Frequently asked

Did this BPC-157 study include people?

No. It tested two engineered fusion proteins containing the BPC-157 sequence in rats with ethanol-induced acute gastric ulcers. The accessible record reports no human outcomes.

Were the tested proteins the same as ordinary BPC-157?

No. One construct attached BPC-157 to gamma-glutamyltranspeptidase and the other attached it to the fluorescent protein mScarlet. The abstract does not establish that either behaved like isolated BPC-157.

Does the rat result prove that BPC-157 heals ulcers?

No. The reported ulcer inhibition belongs to one acute rat model using two fusion proteins. Human efficacy, repeated-use safety, product quality, and comparison with approved ulcer treatments remain unanswered.

Sources

  1. [1]Europe PMC record for Zhang et al. (2026): Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis (PMID 42667535)Tier 1 · primary↩
  2. [2]FDA: Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (BPC-157)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars